Skip to main content
Clinical Trials/NCT01581723
NCT01581723
Unknown
Phase 3

Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial

Chinese University of Hong Kong2 sites in 1 country150 target enrollmentMay 2012

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Urinary Bladder Tumor
Sponsor
Chinese University of Hong Kong
Enrollment
150
Locations
2
Primary Endpoint
Muscle sampling rate
Last Updated
11 years ago

Overview

Brief Summary

Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor. For many years, monopolar transurethral resection of bladder tumor (TURP) has been the gold standard for treatment. However, complications including bleeding, bladder perforation and inadequate sampling of deep tumor biopsy remain the major concerns. Recently published papers suggested that the newer bipolar TUR technology has similar surgical outcomes but less complications comparing with monopolar TUR. In this study, investigators will investigate the benefit of new technology as compared with conventional monopolar resection on tumor clearance, complication and recurrence rates.

Detailed Description

Transurethral resection (TUR) of bladder tumor is one of commonest procedures in urology practice. It is the surgery of choice for staging and treating non-muscle invasive bladder cancer. Short lengths of hospital stay, simple and safe are the main advantages of the surgery. Conventional TUR is performed with monopolar diathermy, which commonly elicits obturator reflexes in lateral-located tumor. However, it is not without complication. Bleeding and bladder perforation with or without obturator reflex are the most significant complications after TUR of bladder tumor. The charring effect of monopolar is also a concern as the diagnosis of muscle invasion by tumor is determined by the integrity of tumor base biopsy. Mariappan et al. reported that as high as 33% of the specimen had no detrusor muscle present for assessment. The absent of muscle not only affect the staging procedure but also associated with higher cancer recurrence rate. Bipolar resection has been widely used in transurethral resection of prostate (TURP). As compared with the traditional monopolar technology, the electric current passes through the instrument sheath. The advantage of bipolar technology includes less obturator reflex, good hemostasis and early recovery. Study has showed that the cautery artifact is more severe on monopolar resection as compared with bipolar in prostate tissues. Due to the clean and precise cutting, there will be less charring on the specimen and thermal injury to peripheral tissues. Applying to bladder tumor resection, this will improve the staging accuracy with better determination of the depth of invasion. Furthermore, with the use of saline instead of glycine as irrigation fluid, risk of TUR syndrome is minimized. There is no randomized trial on the benefit of using bipolar instrument on TUR bladder cancer. In this study, investigator will investigate the role of bipolar technology in TUR bladder cancer as compared with traditional monopolar resection.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
September 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eddie SY Chan, MD

Dr.

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • Adult male or female patients (age ≥ 18)
  • Patients who have diagnosed with bladder cancer (either primary or recurrent) by cystoscopy

Exclusion Criteria

  • Patients who are scheduled for second TUR within 6 weeks after the previous TUR

Outcomes

Primary Outcomes

Muscle sampling rate

Time Frame: An expected average of 7 days post operation

To assess the charring effect to the integrity of the tumor base biopsy

Incidence of TUR syndrome

Time Frame: Intra-operation and up to 7 days post operation

Secondary Outcomes

  • Recurrence rate of bladder cancer(3 months and 6 months after surgery)

Study Sites (2)

Loading locations...

Similar Trials